ADC Therapeutics (ADCT) Depreciation & Amortization (CF) (2019 - 2025)
ADC Therapeutics has reported Depreciation & Amortization (CF) over the past 7 years, most recently at $362000.0 for Q2 2025.
- Quarterly results put Depreciation & Amortization (CF) at $362000.0 for Q2 2025, up 11.04% from a year ago — trailing twelve months through Mar 2026 was $362000.0 (down 73.09% YoY), and the annual figure for FY2025 was $705000.0, down 47.15%.
- Depreciation & Amortization (CF) reached $362000.0 in Q2 2025 per ADCT's latest filing, up from $342000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.1 million in Q4 2022 and bottomed at $174.0 in Q1 2021.
- Median Depreciation & Amortization (CF) over the past 5 years was $294500.0 (2023), compared with a mean of $238106.7.
- The largest annual shift saw Depreciation & Amortization (CF) plummeted 99.88% in 2021 before it surged 312357.82% in 2022.
- Over 5 years, Depreciation & Amortization (CF) stood at $339.0 in 2021, then soared by 312357.82% to $1.1 million in 2022, then plummeted by 68.37% to $335000.0 in 2023, then rose by 1.79% to $341000.0 in 2024, then increased by 6.16% to $362000.0 in 2025.
- Business Quant data shows Depreciation & Amortization (CF) for ADCT at $362000.0 in Q2 2025, $342000.0 in Q1 2025, and $341000.0 in Q4 2024.